At the 2021 Society for Immunotherapy of Cancer (SITC) conference held in November 2021, IsoPlexis presented how to leverage powerful, proteomically active single cells and their genetic drivers, identified simultaneously via single-cell transcriptomic and proteomic analyses on IsoPlexis’ new DuomicTM platform.
These powerful single-cell subsets of highly functional superhero cells are critical to driving longer term response in cell and immune therapies via functional proteins. The presentation highlighted data on how to use these superhero cells for clinical CAR-T studies and preclinical development, clinical combination checkpoint inhibitor studies, and immune therapy discovery.
Revealing Genetic Drivers of Highly Functional CAR-T Cells
Engineered to correlate a cell’s instruction with its function, Duomic captures both mRNA expression data and highly multiplexed functional protein activity. The system brings transcriptomics and functional proteomics together on a single chip to create an integrated cell behavior platform – one that provides critical insights routinely missed by probing for just a single analyte.
The IsoPlexis Duomic platform was used to simultaneously measure the proteomic and gene expression (mRNA) levels of individual CD8+ CAR-T cells in response to specific antigen stimulation. Two distinct populations of cells were identified, one with low polyfunctionality and one with high polyfunctionality. Both subpopulations had a unique gene expression profile, indicating the genes that are potentially regulating the polyfunctional protein expression of the cells.1
Integrative data analysis was performed using the IsoSpeak software and data obtained with the Duomic technology to find the genetic drivers of the biologically powerful responses. These data provide insight into the link between polyfunctionality and the genetic make-up of individual cells.1
In addition, by using this technology, both transcriptomic and functional proteomic data can be linked directly from the same single cell, across many cells in parallel, enabling a direct connection for the first time to the gene regulatory networks that drive critical functional proteomic reactions in various cell types. This type of data will ultimately help researchers continue to accelerate the creation of advanced medicines.1
With the use of IsoPlexis’ Duomic platform, a new era of single-cell functional proteomics and transcriptomics has begun. Researchers are now able to better understand what regulates superhero immune cells or supervillain tumor cells, opening the door to regulating these superpowered cells ourselves with transcription and translation networks.
Contact us to learn more about how Duomic helps visionary researchers like you accelerate in vivo biology by identifying correlations between a cell’s instruction and its true function.